The diagnosis of Parkinson's disease (PD) often remains a clinical challenge.
A C C E P T E D M A N U S C R I P T 1 Introduction
Parkinson's disease (PD) is a complex neurodegenerative disorder, influenced by a wide variety of genetic and environmental risk factors, and characterized by heterogeneous motor and non-motor symptoms [1] .
Currently, only symptomatic treatments are available for PD. For the development of disease-modifying treatments, a more reliable diagnosis is regarded as an important intermediate step [2] . However, to date, the commonly used clinical diagnostic criteria for PD (UK Parkinson's Disease Society Brain Bank criteria) only achieve around 76% specificity [3] . The more recently refined MDS Clinical Diagnostic Criteria for PD [4] were validated for the first time this year with 88.5% specificity, and include a number of clinical signs that can only be properly evaluated after several years of disease duration [5] .
Previous efforts to improve the diagnosis for PD via objective molecular profiling methods [6] [7] [8] [9] [10] [11] [12] [13] [14] and neuroimaging approaches [15] [16] [17] have led to the identification of new measurable alteration patterns in PD; however, no sufficiently robust, reproducible, and clinically validated diagnostic biomarker signature could be derived from these studies. The challenges that may have prevented a more successful development of diagnostic biomarker models include the high heterogeneity of PD in terms of clinical phenotypes, differences in genetic background, comorbidities, lifestyle and diet; the scarce availability of samples for the early pre-symptomatic stages of PD; and a wide range of pre-analytical confounding factors including sample storage duration and time delay between sample collection, among others [18] . Moreover, previous studies on metabolome changes in PD have mainly focused on systemic metabolic profiles alone. A combination with other modalities, such as PET, has not been performed but could provide important information about the relationship between local and systemic changes, both in terms of diagnostic usefulness and understanding of pathophysiology.
Here, instead of proposing a new biomarker signature, we investigate the added value of integrating two previously explored biomarker approaches for predictive model building: Neuroimaging data from positron emission tomography (PET) measurements using the tracers 3,4-dihydroxy-6- parkinsonian syndromes [19, 20] . While it provides significant pathophysiological
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insights [15] , PET imaging is expensive and tim e-consum ing. Considered alone without other types of m easurements, it m ay still leave room for uncertainty.
By contrast, m etabolomics profiling of blood biospecimens is a cost -effective m easurem ent approach requiring lim ited effort s by the patient. Previous m etabolom ics studies using blood and cerebrospinal fluid sam ples have shown significant m etabolite alterations in PD patients com pared to unaffected controls [6, 21] , but the data sets have been insufficient to assess the general predictive value of m etabolite profiles for PD diagnosis, and have not been assessed for their com plem entary predictive value when com bined with PET im aging data. So it rem ains unknown to which extent an integrative approach sheds further light on the pathophysiological cascade in PD.
In order to address these challenges, we present two types of analyses in this study: 
Methods

Study cohort
60 PD patients were recruited at the University Hospital Cologne (UHC) and collaborating community neurologist offices. All patients were diagnosed by an experienced m ovement disorder specialist (CE). Additionally, 15 age-and gender-matched neurologically healthy controls were included. Their num ber was lim ited due to ethical considerations concerning the use of radioactive tracers in healthy subjects , with restrictions im posed by the local ethics com mittee, the federal office for radiation protection and Germ an federal law.
Criteria for participation in the study were age over 40 years and absence of dem entia or conditions directly im pairing brain function. In the PD group, Hoehn and Yahr (H&Y) stage I-III and tolerability of com plete m edical OFFstate (i.e. wash-out of dopam inergic m edication, see below) were required. A subset of 18 subjects from the PD group additionally underwent a follow -up exam ination after one year. Clinical characteristics at baseline were sim ilar between the whole PD group and t he follow-up subgroup. The study was approved by the local ethic s com m ittee of the Medical Faculty of the A C C E P T E D M A N U S C R I P T
Biospecim en collection and processing
Blood sam ples were collected at UHC on the m orning of PET scanning (either FDG or FDOPA, as they were perform ed on separate days). 
Metabolite extraction and GC-M S data acquisition
GC-M S m etabolom ics data quality control, filtering and pre -processing
All GC-MS runs were quality controlled by internal standa rd evaluation. In (FDOPA) was generated and used for the following analysis.
PET im aging data pre-processing
Pre-processing of PET data was perform ed using SPM12 in Matlab (http://www.fil.ion.ucl.ac.uk/spm/software/spm 12). Each subject's averaged FDG and FDOPA im ages were co-registered, centred on the anterior com m issure, and aligned horizontally. Spatial norm alization to MNI space was performed using tracer-specific tem plates available on the SPM website. 
Statistical analyses, m achine learning and cross -validation
The em pirical Bayes m oderated t-statistic [26] was applied to the preprocessed FDOPA and FDG PET im aging data in order to identify and visualize the m ost significantly affected brain regions in PD patients com pared to controls in both datasets. A whole-brain voxel-based approach was chosen for both m ethods, rather than the ratio of specific vs. nonspecific uptake ratio for FDOPA, thereby including e xtrastriatal regions .
Sim ilarly, for the GC -MS m etabolomics data, dedicated statistical tests were applied for supervised feature selection, including the Welch's t-test to
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com pare baseline PD vs. control sam ples, and the paired t-test to com pare the second clinical visit for PD patients vs. the baseline visit m easurem ents .
These tests were chosen to exploit the approxim ate norm al distribution of the data. For all statistical tests applied, the resulting p -values were adjusted for m ultiple hypothesis testing using the m ethod by Benjam ini and Hochberg [27] .
Machine learning m odels for supervised sam ple classific ation were trained and tested on the PET im aging and m etabolomics datasets using both a 50% random training/test set split and a leave-one-out cross -validation. Two different m odel building algorithm s were tested and com pared : A linear support vector m achine (SVM) [28] to assess the separability between PD patients and controls via a linear m odel, and a random forest algorithm [29] (RF, with 250 decision trees ) to investigate whether a hyper -rectangular partitioning of the input feature space reflects the com plexity of the data m ore adequately than a linear approach. The predictive perform ance was evaluated using Receiver Operating Characteristic (ROC) curves for the 50% training/test set split, and averaged accuracies for the cross -validation runs.
The whole evaluation procedure was applied both to the individual datasets and to com binations of their standardized attributes , with two different Gaussian sm oothing filters applied to PET im aging data (see PET im aging data pre-processing).
Results and Discussion
Baseline m etabolom ics differential abundance analysis (PD vs. control)
The glutathione content, and led to increased levels of the oxidative stressresponsive transcription factor Gadd153/CHOP [30] . [30] . Dehydration causing urea increases can be excluded in our study as the recruited subjects m aintained norm al hydrat ion regim es. The increases of the fatty acids hexadecanoic acid and octadecanoic acid in PD patients could result
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A C C E P T E D M A N U S C R I P T from an increased fat breakdown into glycerol and fatty acids that could be either diet-or pathology-related. In the latter case, fatty acid accum ulation m ay be associated with alterations in fatty acid oxidation, which have previously been proposed to play a key role in the pathophysiology of PD [32] . Specifically, the increase in fatty acid oxidation is thought to counteract progressive neuronal cell death by upregulating neuroprotective agents, such as the brain-derived neurotrophic factor (BDNF) [33] . Interestingly, recent studies in a subclinical PD cohort have indicated that patients with an ascorbic acid deficiency later on developed PD m ore frequently [35] .
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Apart from this , m inor changes were observed in m annose (p = 0.03, FC = 1.15, FDR=0.32), which could result from decreased levels of m annose
binding lectin (MBL) in response to inflam mation in PD as discussed previously [21] . MBL plays a key role in innate im m une system recognition of pathogenic agents . Thus, the increased free m annose found in this study m ight reflect perturbed im m une signals in PD. This hypothesis is in line with previous studies proposing a m echanistic link between reduced MBL levels and the m ost com m on neurodegenerative disorder, Alzheim er's disease [36] .
In a previous independent metabolomics-based study involving members of our research group, we had also identified increased threonic acid levels, but in cerebrospinal fluid (CSF) from early-stage PD patients com pared to healthy control subjects from the DeNoPa cohort [21] . Further longitudinal m easurem ents on independent cohorts and at shorter tim e intervals will be required to confirm these alteration trends.
Differential feature analysis of FDOPA and FDG PET im aging data
A voxel-wise group comparison was first performed between PD patients' and controls' PET signals . W e used the em pirical Bayes m oderated t -statistic across all voxels with non-zero variance. For FDOPA, two voxel clusters located bilaterally in the posterior part of the putam en displayed significant differences after m ultiple hypothesis testing adjustm ents (FDR < 0.05, see red areas highlighted in Fig. 3 ). This finding is a well -known feature of PD as it reflects the loss of dopam inergic term inals projecting from the substantia nigra (SN), pars com pacta (SNc) to the po sterior putam en subregion of the striatum [37] [38] [39] .
By application of the sam e m ethod to the FDG-PET dataset, we identified two clusters in the cerebral peduncles of the lower m idbrain, where the SNc is
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located (see green areas highlighted in Fig. 3 ). As degeneration of the cell bodies in SNc leads to the onset of m otor sym ptoms [37] , it seem s intuitive to find hypom etabolism in this region at a m iddle disease stage of our patients [40] . A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T exclusively in the striatum, a clearly weakened signal is seen in the majority of midstage PD cases [19] . By contrast, FDG reflects neuronal activity in general, and while there are distinct FDG changes in PD, they occur as a more complex covariance pattern rather than absolute local changes [16] .
In order to explore the usefulness of the collected data for estim ating a quantitative disease outcome, we evaluated to which extent the UPDRS part 3 (m otor score), assessed in the off-m edication state, could be predicted from the data [34] . As the Random Forest algorithm with 250 trees had provided the best prediction results in the previous analyses, regression models were trained to estimate the motor score sum from the FDOPA and FDG PET Independent analyses on distinct cohorts will be necessary to confirm these indicative trends.
Conclusions
The complex, multifactorial nature of Parkinson's disease (PD) is reflected by a wide range of measurable alteration patterns in human tissues and body fluids, as illustrated by the data presented here and in other independent studies. Most of the previous work on metabolic biomarker models for PD has focused on a single biospecimen or type of measurement. While our new analysis is based on a limited set of measurements and will require further validation on other cohorts, its integration of two very diverse data types, blood metabolomics and brain PET imaging data, is unique. The results suggest that capturing different types of PDassociated changes via highly diverse readouts can increase the predictive performance of such models and also sheds further light on the ongoing pathophysiological cascades. Specifically, the observed metabolite alterations provide pointers to the injury-response processes involved in the disease, as we found metabolite changes associated with oxidative stress and inflammation.
Although to date predictors derived from metabolomics datasets are less performant than those derived from neuroimaging data, metabolomic profiling could give diagnostic clues when PET is not available or would not be practical. The scope of this study was however limited to investigating the relative difference in crossvalidated predictive performance between using PET data in isolation and combining it with metabolomics. W hile the available sam ple sizes provided sufficient statistical power to identify significant differences between patients and controls in both neuroim aging and m etabolom ics analyses , further m easurements are warranted in order to identify PD -associated alterations with sm aller effect size and to substantiate the gener alizability of the A C C E P T E D M A N U S C R I P T predictive m odels. Thus, in order to develop and validate a new biomarker machine learning model as an improved diagnostic test, the most stable and generalizable predictive features will still need to be identified in independent cohorts. Future extensions of this work should also include samples from subjects with clinical diagnoses similar to PD, e.g. from cohorts focusing on atypical forms of parkinsonism and essential tremor. Furthermore, the added predictive value of metabolomics data should be assessed in integrative analyses with other relevant types of neuroimaging data, e.g. dopamine transporter SPECT imaging, which is more commonly applied in practice than FDOPA PET. Combined with known PDassociated risk factors or prodromal symptoms, such as REM sleep behaviour disorder, hyposmia and constipation [41] , refined metabolomics profiling could ultimately be helpful in selecting subjects for disease modifying studies. Thus, while significant progress is still warranted for increasing the accuracy and robustness of predictive machine learning models for PD, our study demonstrates that metabolic signatures can help distinguish PD patients from controls.
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